Facebook
Twitter
LinkedIn
Forward
Spotlight on Desmoid Tumors: Bridging Knowledge Gaps for Optimal Patient Care (Boston)
Overview
Join us for this 1-hour, CME-certified live dinner program to gain expert insights into the evolving treatment landscape for desmoid tumors. In an engaging discussion format, Candace Haddox, MD, and David Shulman, MD, will explore key aspects of desmoid tumor management—including disease pathogenesis, diagnosis, treatment selection, and adverse event management—through patient case discussions and review of the latest clinical data.
Learning Objectives
- Describe evidence-based strategies for the diagnosis of desmoid tumors, including molecular profiling, imaging modalities, and the role of multidisciplinary team consultation.
- Discuss the efficacy, safety, and expected outcomes of standard-of-care therapies with patients under active surveillance considering systemic treatment.
- Develop individualized treatment plans for patients with progressive, unresectable, recurrent, or refractory desmoid tumors based on available clinical data, clinical guidelines, and patient-specific factors.
- Recognize, assess, and manage treatment-related adverse events associated with systemic therapies.
Target Audience
This activity is designed to educate oncology physicians as well as advanced practice providers, physician assistants, pharmacists, and nurse specialists involved in the care of patients with desmoid tumors.
This program is supported by an independent educational grant from SpringWorks Therapeutics, Inc.
Privacy Statement: For online registration, we take precautions to protect your information. When you submit sensitive information via the website, your information is protected both online and offline. In order to use this website, a user must first complete the registration form. During registration, a user is required to give certain information (such as name, email, mailing address, and payment information). This information is confidential and will only be used to contact you regarding your registration.
Please note: times are subject to change. Please check the syllabus for the most current version of the agenda upon arriving at the summit.
Commercial Support: This activity is supported by an independent educational grant from SpringWorks Therapeutics, Inc.
All Times Listed in Local Time Zone
Saturday, July 26, 2025 | |
| 6:15pm | Welcome & Introduction |
| 6:15pm | Spotlight on Desmoid Tumors: Bridging Knowledge Gaps for Optimal Patient Care » Candace Haddox, MD - Instructor of Medicine - Dana-Farber Cancer Institute - Boston, MA » David Shulman, MD - Associate Professor of Pediatrics, HMS - Dana Farber Cancer Institute - Boston, MA |
| 7:15pm | Closing Remarks |
Faculty
Candace Haddox, MD
Instructor of Medicine
Dana-Farber Cancer Institute
Boston, MA
Dr. Candace Haddox is an Instructor in Medicine at Harvard Medical School, and a medical oncologist and clinical/translational investigator in the Sarcoma Center and the Center for Cancer Therapeutic Innovation at Dana-Farber Cancer Institute. Dr. Haddox's research focuses on developing novel therapies rooted in sarcoma biology and determining mechanisms of treatment response and resistance.
Dr. Haddox received her Bachelor of Science in neurobiology from the University of Miami. She completed a post-baccalaureate research fellowship at the National Institutes of Health and received her Medical Degree from the University of South Florida. Dr. Haddox completed a residency in Internal Medicine at the Mayo Clinic in Rochester, Minnesota, and a fellowship in Medical Oncology at Duke University, where she also served as Chief Fellow. She joined the faculty at Dana-Farber Cancer Institute in 2021, where she currently sees patients with sarcomas and leads clinical trials in early drug development.
David Shulman, MD
Associate Professor of Pediatrics, HMS
Dana Farber Cancer Institute
Boston, MA
David is a Pediatric Oncologist and clinical/translational researcher at Dana-Farber Cancer Institute, and an Assistant Professor of Pediatrics at Harvard Medical School. He is the director of the DFCI AYA Sarcoma Program. His NIH-funded research program is dedicated to improving outcomes for adolescents and young adults (AYA) with sarcomas through investigation of novel approaches to therapy and circulating tumor DNA (ctDNA) as a clinical biomarker. David's clinical focus is on the care of AYAs with sarcomas.
Disclosures
Horizon CME requires all planners, faculty, and other contributors to disclose any financial relationships with an ACCME defined ineligible company within the past 24 months and Horizon CME has resolved any conflicts prior to this educational activity.
Planners
*Horizon CME has mitigated and resolved all relevant financial relationships
Faculty *
Those others involved in the planning of this activity disclosed no relevant financial relationships with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients.
Other Contributors *
All other non-faculty contributors and others involved in the planning, development and editing/review of the content disclosed no relevant financial relationships with any entity producing, marketing, re-selling or distributing health care goods or services consumed by or used on patients.
Available Credit
- 1.00 AMA PRA Category 1 Credit™
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME). Horizon CME is accredited by the ACCME to provide continuing medical education for physicians.
Horizon CME designates this Live activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.